comprehensive -WSS

comprehensive

author：knowledge 2025-08-08 05:32:52 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Stem cell treatment guidelines are released by FDA

explore

WSS

Congress extends some pandemic preparedness programs

The (many) problems with a new study criticizing cancer screening

Some top drug companies are starting to take action on climate

Medicare innovation center doesn’t save money, experts say

AstraZeneca chief proposes a novel edit to the drug pricing bill

Weighted lottery helped low

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare details structure of new drug price negotiation program

Advances in CAR

Novavax promises a turnaround & Lilly roils the obesity market

Will an HIV vaccine ever be a reality?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What will Novo Nordisk's VC do with its influx of cash?

Tori Bowie and the unacceptable rates of Black maternal death

6 solutions to address cancer drug shortages and others

Tori Bowie and the unacceptable rates of Black maternal death

What we owe ALS patients — and why one company fell short

explore

Trump surgeon general acknowledges mistakes during Covid

A rare thyroid diagnosis led to unexpected, all

How to protect patients from sexual assault

The 10 drugs up first for Medicare price negotiation

Study points to new risk in gene therapy death of Terry Horgan

Study points to new risk in gene therapy death of Terry Horgan

hotspot

leisure time

explore

hotspot